Medicare Payment and Reimbursement
HFMA Comments on the CY18 OPPS/ASC Proposed Rule
Published
September 13, 2017
2:58 pm
|
Updated
November 7, 2022
8:35 am
HFMA would like to thank CMS for the opportunity to comment on its analysis and discussion of the Medicare reimbursement decisions addressed in the 2018 Proposed Rule. Our members would like to comment on the proposals related to:
- Alternative Payment Methodology for Drugs Purchased under the 340B Drug Program
- Proposed Changes to the Inpatient-Only (IPO) List
- Potential Revisions to the Laboratory Date-of-Service Policy
- Proposed New ASC Quality Measures
